Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
NCT06816394Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in extrapulmonary small cell carcinoma (EPSCC) and neuroendocrine carcinoma (NEC), sponsored by National Taiwan University Hospital. Primary endpoint: Objective Response Rate at 8 weeks. Started Jan 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
extrapulmonary small cell carcinoma (EPSCC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06816394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816394.